SRC and head and neck squamous cell carcinoma: Based on these results, a randomized, placebo-controlled window trial on the use of c-Src inhibitor dasatinib in combination with erlotinib was conducted to assess dasatinib capability to overcome tumor resistance to erlotinib in HNSCC patients.